CB-03-10
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Refractory Solid Tumors
Conditions
Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
Trial Timeline
Jun 14, 2022 → Jun 1, 2026
NCT ID
NCT03863145About CB-03-10
CB-03-10 is a phase 1 stage product being developed by Cosmo Pharmaceuticals for Advanced Refractory Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03863145. Target conditions include Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Refractory Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03863145 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Refractory Solid Tumors